Figure 7
Figure 7. Human hematopoietic engraftment in NOD/SCID mice by CD34+ACE+ fetal liver cells. Representative examples displaying analysis of BM from NOD/SCID recipients of CD34+ACE+ cells sorted from a 14-week human fetal liver. Analyses were performed 4 months after transplantations. (A) Percentage of human CD45+ cells in individual animals that received a transplantation of 1 × 103, 2 × 103, 5 × 103, and 10 × 103 CD34+ACE+ cells. Horizontal lines represent the average percentage of human CD45+ cells in each group. (B) Representative example of multilineage human hematopoietic engraftment in an animal that received a transplantation of 1 × 103 cells. (C) Four mice that received a transplantation of 1 × 103, 2 × 103, 5 × 103, and 10 × 103 CD34+ACE+ cells. The percentages indicate the significant proportion of human CD45+ cells within the BM represented by CD34-expressing cells.

Human hematopoietic engraftment in NOD/SCID mice by CD34+ACE+ fetal liver cells. Representative examples displaying analysis of BM from NOD/SCID recipients of CD34+ACE+ cells sorted from a 14-week human fetal liver. Analyses were performed 4 months after transplantations. (A) Percentage of human CD45+ cells in individual animals that received a transplantation of 1 × 103, 2 × 103, 5 × 103, and 10 × 103 CD34+ACE+ cells. Horizontal lines represent the average percentage of human CD45+ cells in each group. (B) Representative example of multilineage human hematopoietic engraftment in an animal that received a transplantation of 1 × 103 cells. (C) Four mice that received a transplantation of 1 × 103, 2 × 103, 5 × 103, and 10 × 103 CD34+ACE+ cells. The percentages indicate the significant proportion of human CD45+ cells within the BM represented by CD34-expressing cells.

Close Modal

or Create an Account

Close Modal
Close Modal